EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan

Andre F Carvalho, Chih-Wei Hsu, Eduard Vieta, Marco Solmi, Wolfgang Marx, Michael Berk, Chih-Sung Liang, Ping-Tao Tseng, Liang-Jen Wang

Psychotherapy and Psychosomatics · 2024

DOI: 10.1159/000535777 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Psychotherapy and Psychosomatics, 2024. Verfasst von Andre F Carvalho und 8 weiteren Autor:innen. Beteiligte Einrichtung: IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Institute, School of Medicine, Barwon Health, Deakin University, Geelong, Vi…. Hauptthemen laut MEDLINE: Bipolar Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to estimate all-cause mortality in patients after a first-episode mania (FEM) and examine whether six guideline-recommended medications can reduce mortality.

Methods

The cohort included population-based FEM samples and matched controls from Taiwan, spanning 2007 to 2018. The primary outcomes assessed were all-cause/suicide-related mortality, while the secondary outcome focused on mortality associated with pharmacological treatments. We compared mortality in post-FEM patients and age-/sex-matched controls without any diagnosed bipolar disorders and patients with and without psychopharmacological treatment using Cox regression analysis, respectively. Statistics were presented with time-to-event adjusted hazard ratios (AHRs) and 95% confidence intervals (CIs).

Results

The study included 54,092 post-FEM patients and 270,460 controls, totaling 2,467,417 person-years of follow-up. Post-FEM patients had higher risks of all-cause mortality (AHR 2.38, 95% CI: 2.31–2.45) and suicide death (10.80, 5.88–19.84) than controls. Lithium (0.62, 0.55–0.70), divalproex (0.89, 0.83–0.95), and aripiprazole (0.81, 0.66–1.00) were associated with reduced all-cause mortality compared to non-users. There were no significant all-cause mortality differences for quetiapine (0.95, 0.89–1.01), risperidone (0.92, 0.82–1.02), and paliperidone (1.24, 0.88–1.76) users. When accounting for drug action onset times in sensitivity analyses, only lithium significantly reduced all-cause mortality (AHR range 0.65–0.72). There were 35 and 16 suicide deaths in post-FEM patients and controls, respectively. No drug had a significant effect on suicide deaths (lithium: 6; divalproex: 7; aripiprazole: 0; quetiapine: 10; risperidone: 4; paliperidone: 1).

Conclusion

Post-FEM patients had a higher risk of all-cause/suicide-related mortality, and lithium treatment might reduce all-cause mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderAntipsychotic AgentsHumansLithiumValproic AcidQuetiapine FumarateAripiprazoleRisperidoneManiaRetrospective StudiesPaliperidone PalmitateTaiwan

Stichwörter der Autor:innen

Bipolar disorderDepressionLithiumManiaMortality

Substanzen

LithiumValproic AcidQuetiapine FumarateAripiprazoleRisperidonePaliperidone PalmitateAntipsychotic Agents

Autor:innen und Institutionen

  • IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Institute, School of Medicine, Barwon Health, Deakin University, Geelong, Victoria, Australia.
  • Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Bipolar and Depressive Disorders Unit, Hospital Clinic, IDIBAPS, CIBERSAM, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.
  • Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada.
  • Department of Mental Health, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa, Ottawa, Ontario, Canada.

Zitieren

APA

Carvalho, A. F., Hsu, C. W., Vieta, E., Solmi, M., Marx, W., Berk, M., Liang, C. S., Tseng, P. T., & Wang, L. J. (2024). Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000535777

Vancouver

Carvalho AF, Hsu CW, Vieta E, Solmi M, Marx W, Berk M, et al. Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan. Psychotherapy and Psychosomatics. 2024. doi:10.1159/000535777

BibTeX
@article{Carvalho2024,
  author = {Carvalho, Andre F and Hsu, Chih-Wei and Vieta, Eduard and Solmi, Marco and Marx, Wolfgang and Berk, Michael and Liang, Chih-Sung and Tseng, Ping-Tao and Wang, Liang-Jen},
  title = {Mortality and Lithium-Protective Effects after First-Episode Mania Diagnosis in Bipolar Disorder: A Nationwide Retrospective Cohort Study in Taiwan},
  journal = {Psychotherapy and Psychosomatics},
  year = {2024},
  doi = {10.1159/000535777}
}
Kostenlos starten →